AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04021615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive physical therapy rehabilitation program combined with inspiratory muscle training
Description: A threshold inspiratory muscle trainer will be connected to the artificial airway with 15 mm and 22 mm adaptors. Training bouts consist of three to five sets of six repetitions breathing through the trainer. Training will be conducted with the patient in bed with an approximately 30° head-up tilt and with intensity about 40 %- 50 % of maximal inspiratory pressure. Patients will be returned to mechanical ventilation for rest between training sets as needed. Three to five sets of six training breaths will be completed for a total of 18 to 30 training breaths per session. Following each training set, the patient indicated a rating of perceived inspiratory exertion on modified Borg scale . The study group will also receive comprehensive rehabilitation program consist of upper-extremity exercises, lower extremity exercises, pedaling exercises, trunk control exercises and bedside functional training
Study NCT04021615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional chest physical therapy rehabilitation program combined with inspiratory muscle training
Description: The same inspiratory muscle training for the study group combined with the traditional physical therapy program consist of positioning , modified postural drainage , percussion , vibration.
Study NCT01039688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at a dose of 5 mg BID for 24 months
Study NCT01039688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at a dose of 10 mg BID for 24 months
Study NCT00734344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600 mg once daily
Study NCT00734344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitibine
Description: 200mg once daily
Study NCT01771952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synvisc-One™
Description: A single 6cc injection of Synvisc-One™ will be utilized in this study.
Study NCT01771952 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: A single needle stick without arthrocentesis or injection.
Study NCT01289080 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-34712
Description: administered orally
Study NCT03352375 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: Interventions used for airway safety and ventilation during surgical procedures
Study NCT01039688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disease-modifying antirheumatic drug
Description: Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months
Study NCT04507035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride capsules
Description: Using anlotinib of 2 cycles as the first-line therapy.
Study NCT00156715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
Study NCT01070498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (TSO)
Description: Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
Study NCT01801878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose SVF cell
Description: adipose SVF cell transfer to the half of irradiated breast
Study NCT03301025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 150 mg capsule, one h preinduction of general anesthesia
Study NCT03301025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: given a placebo identical capsule once one hour before anesthesia
Study NCT04102462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: Capsules
Study NCT04102462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Capsules
Study NCT00734344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil once daily
Description: 300mg once daily
Study NCT02040714 — intervention group
Intervention type: PROCEDURE
Intervention: Multiple Epiphyseal Drilling
Description: Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.
Study NCT00475319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: comparison of different dosages of drug
Study NCT00475319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% OPC-12759 ophthalmic suspension
Description: comparison of different dosages of drug
Study NCT00475319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% OPC-12759 ophthalmic suspension
Description: comparison of different dosages of drug
Study NCT00482378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate
Description: 90 mg by IV monthly.
Study NCT00482378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4 mg by IV monthly.
Study NCT04542681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - 1st Cycle
Description: Subjects will receive a single SQ injection of placebo/normal saline
Study NCT00734344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil twice daily
Description: 300mg twice daily
Study NCT00482378 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sm 153 lexidronam
Description: 0.5 mCi/kg or 1 mCi/kg by IV.
Study NCT03544554 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model. Within the scope of the counseling and training program
Description: The intervention group was provided with a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model.
Study NCT01694420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (FDC) ELV/COBI/FTC/TDF
Description: Antiretroviral treatment
Study NCT01755195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumor growth, metastasis, and angiogenesis, and targets primarily mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2).
Study NCT01682499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium gluconate and magnesium sulfate
Description: Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
Study NCT04470492 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Doctormate®+Medical Management
Description: Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) twice daily and conventional medication for 3 months.
Study NCT04470492 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Medical Management
Description: Patients will be treated with conventional medication for 3 months.
Study NCT01303380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study NCT02689232 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Study NCT02689232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma
Study NCT02689232 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelets Concentrate
Study NCT02689232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelets Concentrate
Study NCT02689232 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cryo Precitipitate
Study NCT02689232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryo Precitipitate
Study NCT03279783 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LCI (Linked color imaging)
Description: Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked color imaging)
Study NCT00093002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 250 mg \& 500 mg intramuscular injection
Study NCT02317406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biostime probiotics sachet children's formula
Description: Biostime probiotics sachet children's formula,1.5g Oral Single dose
Study NCT02317406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Biostime probiotics sachet children's formula（placebo）
Description: Biostime probiotics sachet children's formula（placebo）,1.5g Oral Single dose
Study NCT04289454 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Flavor additive
Description: Various flavor additives will be tested (vs. no added flavor) to determine which show promise for making KE drinks taste less unpleasant
Study NCT01233843 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: carboplatin
Description: 70 mg per m2 and per day for four days. day 1; day 22; day 43
Study NCT01233843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: 70 mg per m2 and per day for four days. day 1; day 22; day 43
Study NCT01233843 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5 fluorouracil
Description: 600mg per m2 per day for four days. 3 cycles day 1; day 22; day 43
Study NCT01233843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 fluorouracil
Description: 600mg per m2 per day for four days. 3 cycles day 1; day 22; day 43
Study NCT01233843 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: total dose: 70 grays. The patient receives 2 grays per day; five days a week during 7 weeks
Study NCT03245723 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Function Testing
Description: Subjects will undergo Spirometry and Plethysmography
Study NCT03245723 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary Function Testing
Description: Subjects will undergo Spirometry and Plethysmography
Study NCT03245723 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiogram
Description: Subjects will undergo an electrocardiogram to ensure sinus rhythm
Study NCT03245723 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Electrocardiogram
Description: Subjects will undergo an electrocardiogram to ensure sinus rhythm
Study NCT03245723 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Subjects will undergo positron emission tomography to detect images of the heart
Study NCT03245723 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Positron Emission Tomography
Description: Subjects will undergo positron emission tomography to detect images of the heart
Study NCT03245723 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Subjects will undergo positron magnetic resonance imaging to detect images of the heart
Study NCT03245723 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Subjects will undergo positron magnetic resonance imaging to detect images of the heart
Study NCT01233843 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: total dose: 70 grays. The patient receives 2 grays per day; five days a week during 7 weeks
Study NCT03544359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial electrical stimulation (tES)
Description: In tES, a mild electrical current is passed between two or more electrodes placed on the volunteer's head (scalp). In this study, a mild unvarying (constant) electrical 2mA current is passed between two rubber electrodes placed on the head over auditory cortex for 20 minutes per session for 5 consecutive days. Because the electrical current direction (positive/negative) and current amplitude (2mA) does not vary or change during stimulation, this type of tES is also called transcranial direct current stimulation, or tDCS.
Study NCT03544359 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial electrical stimulation (tES)
Description: In tES, a mild electrical current is passed between two or more electrodes placed on the volunteer's head (scalp). In this study, a mild unvarying (constant) electrical 2mA current is passed between two rubber electrodes placed on the head over auditory cortex for 20 minutes per session for 5 consecutive days. Because the electrical current direction (positive/negative) and current amplitude (2mA) does not vary or change during stimulation, this type of tES is also called transcranial direct current stimulation, or tDCS.
Study NCT01404117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod 0.6
Description: Laquinimod 0.6 capsule
Study NCT01404117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod 1.2
Description: Placebo
Study NCT01404117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate or interferon-beta+ Placebo
Description: GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo
Study NCT00103402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Study NCT00103402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03119493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Periodized aerobic interval training
Description: The periodized training program consist in 3 phases: light (I) (training range varying between 20 to 39% of heart rate reserve and active recuperation of 19% of heart rate reserve); moderate (II) (training range varying between 40 to 59% of heart rate reserve and active recuperation of 30% of heart rate reserve) and high (III) (training range varying between 70 to 90 % of heart rate reserve and active recuperation of 50% of heart rate reserve).
Study NCT02655055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high frequency voluntary apheresis blood donation
Study NCT02677259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-beta estradiol
Study NCT02677259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Study NCT01184508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, once daily, for 12 weeks
Study NCT01184508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2300559
Description: 300 milligrams (mg) administered orally, once daily, for 12 weeks
Study NCT01471392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STD Diagnostic Kit (Identigene)
Description: The Identigene STD Test Collection Kit is an at-home kit that allows individuals to utilize the Gen-Probe technology to test for CT and NG in privacy and in a more convenient manner. The primary technology is the approved Gen-Probe APTIMA Combo 2 assay, which is repackaged into the Identigene kit for use by consumers. As such, the laboratory technology and testing method is identical to that of the Gen-Probe APTIMA Combo 2 assay, which has been cleared for in vitro diagnostic use.
Study NCT04542681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MANP - 1st Cycle
Description: Subjects will receive a single SQ injection of MANP at a concentration of 2.5 μg/kg
Study NCT04542681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MANP - 2nd Cycle
Description: Subjects will receive a single SQ injection of MANP 5 μg/kg concentration.
Study NCT02854163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: All eligible patients registered into the study will receive four 150 - 300 mg subcutaneous injections at weekly intervals, followed by regular injections 150mg once a month thereafter for a total of 12 months
Study NCT02677259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone
Study NCT01059721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medialising insertion of patella tendon
Description: surgical treatment of medialising tibial tuberosity
Study NCT03629613 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral antioxidant cocktail
Description: Oral antioxidant cocktail intake will occur after baseline measurements:~Dose 1 (immediately after baseline testing): 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2 (30 minutes after Dose 1): 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E
Study NCT03629613 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Baseline
Description: No oral antioxidant cocktail intake or placebo intake will occur prior to baseline measurements
Study NCT02378441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg and Metformin SR 750mg
Description: co-administration of Atorvastatin 20mg and Metformin SR 750mg
Study NCT02378441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30056 20/750mg
Description: fixed-dosed combination of Atorvastatin 20mg and Metformin SR 750mg
Study NCT02928757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex care clinic as part of the CCKO initiative
Description: The CCKO intervention involves intensive care coordination, defined as: deliberate organization of patient care activities between two or more participants (including the patient) involved in a patient's care to facilitate the appropriate delivery of health care services. Organizing care involves marshaling of personnel and other resources needed to carry out all required patient care activities and is often managed by the exchange of information among participants responsible for different aspects of care. Within CCKO, intensive care coordination will specifically include: 1) the tailored, family/health care provider co-creation and regular updating of care coordination plans for each child which will be 2) facilitated and accounted for by key workers partnering with families.
Study NCT01436565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-121 (SAR256212)
Description: Pharmaceutical form:solution~Route of administration: Intravenous
Study NCT01809392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: 36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
Study NCT01436565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245408
Description: Pharmaceutical form:tablet~Route of administration: oral
Study NCT01891305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161
Study NCT02219178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 25mg days 1 - 14 of 21 day schedule
Study NCT02219178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous bortezomib
Description: 1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule
Study NCT02219178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
Study NCT00992173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultratrace Iobenguane I 131
Description: Subjects will receive an Imaging Dose of 0.1 mCi/kg \[3.7 MBq/kg\] (a minimum dose of 1.0 mCi \[37 MBq\] but not to exceed 5.0 mCi \[185 MBq\]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
Study NCT00566904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epikeia coatings with aspirin
Description: Applied to affected skin area using a roll-on ball applicator
Study NCT01891305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01323608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
Study NCT01323608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo